AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional backing from executives at Meta, OpenAI, and Wiz.
AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional backing from executives at Meta, OpenAI, and Wiz.
